Form 4: Cassava Sciences Director Claude Nicaise Granted 26,500 Stock Options Under Approved Compensation Plan

Cassava Sciences Inc. Director Claude Nicaise was granted 26,500 stock options with an exercise price of $2.11, vesting monthly over one year, as part of the company's amended non-employee director compensation program.

Summary

• Director Claude Nicaise of Cassava Sciences Inc. (SAVA) was granted 26,500 stock options.
• The options have an exercise price of $2.11 per share.
• The grant date for these options was May 23, 2025.
• The options will expire on May 23, 2035.
• The grant was made pursuant to the Amended Non-employee Director Compensation Program, which was approved by stockholders on May 23, 2025.
• The stock options will vest over a one-year period at a rate of 1/12 per month.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine corporate governance event. It's slightly positive as it aligns director incentives with shareholder interests and indicates a standard compensation practice approved by stockholders, but it doesn't convey significant new operational or financial news.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The Amended Non-employee Director Compensation Program was approved by stockholders, indicating good corporate governance and transparency.

Negatives

• The exercise price of $2.11 is relatively low, which could suggest a significant potential dilution if the stock price rises substantially above this level and all options are exercised.

Future Outlook

The granted stock options will vest over a one-year period at a rate of 1/12 per month, indicating a future schedule for the director to gain full ownership rights to the options.

Industry Context

This is a routine compensation event for a director in a publicly traded company, common across various industries, including biotechnology. It reflects standard practices for incentivizing board members.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, aligning director incentives with shareholder value.
• The vesting schedule of one year (1/12 per month) is a standard approach for director equity grants, similar to practices seen in companies like Biogen Inc. or Eli Lilly and Company for their non-executive board members, though specific grant sizes and exercise prices vary based on company size, performance, and compensation policies.
• The exercise price of $2.11, if it represents the market price on the grant date, is typical for at-the-money options.

Corporate Governance

Related Party Transactions

• The grant of 26,500 stock options to Claude Nicaise, a director of Cassava Sciences Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but it also aims to align the director's interests with shareholder value creation. The approval of the compensation program by stockholders suggests their endorsement of this approach.

Next Steps

• The stock options will vest monthly over the next one year.

Key Dates

Keywords

Cassava Sciences, SAVA, Stock Options, Director Compensation, SEC Form 4, Claude Nicaise, Equity Grant, Non-employee Director, Biotechnology, Pharmaceuticals